Melanoma Focus Virtual Regional Meeting

Welcome/Introductions
Dr Mark Harries/Dr Miranda Payne/Susanna Daniels

Stage II Melanoma: Developments as a result from advances in systemic therapies

Associate Professor Alexander van Akkooi, Chair of Melanoma Surgery, Melanoma Institute of Australia

Pharma Exhibition Area / Posters

Virtual Networking:
My Melanoma: Mark Middleton

Pharma Sponsored Symposium: Novartis

Survivorship – A new treatment goal for advanced melanoma?

Session 1: Molecular surveillance of melanoma
Chair: Professor Mark Middleton – Professor of Experimental Cancer Medicine in the Department of Oncology, Consultant Medical Oncologist at the Oxford Cancer and Haematology Centre

Circulating tumour DNA; a new tool for the clinic
Dr Rebecca Lee, Clinical Lecturer in Medical Oncology, The University of Manchester

Biofluid metabolomics – the other liquid biopsy for cancer detection
Dr James Larkin, Lecturer in Biochemistry, Trinity College, Oxford

Q&A

Session 2: Living beyond a stage 4 diagnosis
Chair: Lesley Howells, Maggies Lead Psychologist, Maggies Centre, Oxford

Caroline Kohl (10 mins), Paul Duhig (10 mins), Dr Shelley Petzer (10 mins)

Q&A

Comfort Break

Session 3: Practice changes in oncology

Chair: Dr Ben Fairfax, Wellcome Intermediate Clinical Fellow and Honorary Consultant Medical Oncologist

Using Artificial Intelligence approaches to address an unmet need for melanoma
Dr Rubeta Matin, Consultant Dermatologist and Honorary Senior Clinical Lecturer, Oxford University Hospitals NHS Foundation Trust

Findings from the first UK Census of Skin Cancer Specialist Nurses
Dr Pippa Corrie, Consultant Medical Oncologist, Deeya Kotecha & Jashmitha Rammanohar, Final year medical students Addenbrooke’s Hospital, Cambridge

Melanoma immunotherapy: response and toxicity
Professor Genevieve Boland – Section Head, Melanoma/Sarcoma Surgery, Surgical Director, Termeer Center for Targeted Therapies, Director, Surgical Oncology, Research Laboratories, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School

Q&A

Session 4: MDT – Management of progression on adjuvant treatment (case-based discussions)
Chair: Dr Heather Shaw, Consultant Medical Oncologist, Mount Vernon Cancer Centre
Panel:
Mr Oliver Cassell, Consultant Plastic Surgeon, Oxford University Hospitals
Professor John Wagstaff, Professor of Medical Oncology, Swansea
Dr Steve Watkins, Consultant Oncologist, Birmingham University Hospitals
Professor Genevieve Boland, Section Head, Melanoma/Sarcoma Surgery, Surgical Director, Termeer Center for Targeted Therapies, Director, Surgical Oncology, Research Laboratories, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School

Concluding Remarks and Close
Dr Mark Harries, Chairman Melanoma Focus, Dr Miranda Payne, Organiser